Association of hormone replacement therapy with the risk of gastric cancer: a systematic review and meta-analysis
Sung, H. et al. World Cancer Statistics 2020: GLOBOCAN estimates of worldwide incidence and mortality for 36 cancers in 185 countries. CA A Cancer J. Clin. 71209–249 (2021).
Thrift, AP & El-Serag, HB Burden of gastric cancer. Clin. Gastroenterol. Hepatol. 18534-542 (2020).
Zhang, X. et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroenterology 155347–354 (2018).
Huang, HL et al. Effect and cost-effectiveness of nationwide gastric cancer screening in Japan: a microsimulation modeling study. BMC Med. 18257 (2020).
Arnold, M. et al. Is gastric cancer becoming a rare disease? A global assessment of projected incidence trends to 2035. Intestine 69823–829 (2020).
Ferlay, J. et al. World Cancer Observatory: Cancer tomorrow. Lyon, France: International Agency for Research on Cancer (2020). https://gco.iarc.fr/tomorrow. Accessed November 18, 2021.
Lobo, RA Hormone replacement therapy: current thinking. Nat. Rev. Endocrinol. 13220-231 (2017).
Wells, G. et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the effectiveness of hormone replacement therapy in the treatment and prevention of osteoporosis in postmenopausal women. Endocrine Rev. 23529–539 (2002).
Collaborative group on epidemiological studies of ovarian cancer. Use of menopausal hormones and risk of ovarian cancer: individual meta-analysis of 52 epidemiological studies. Lancet 3851835–1842 (2015).
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: an individual participant meta-analysis of global epidemiological data. Lancet 3941159-1168 (2019).
Lagergren, K., Lagergren, J. & Brusselaers, N. Hormone replacement therapy and oral contraceptives and risk of esophageal adenocarcinoma: systematic review and meta-analysis. Int. J.Cancer 1352183-2190 (2014).
Johnson, J.R. et al. Menopausal hormone therapy and risk of colorectal cancer. Cancer epidemiology. Biomark. Prev. 18196–203 (2009).
Jang, YC, Huang, HL & Leung, CY Association of hormone replacement therapy with mortality in colorectal cancer survivors: a systematic review and meta-analysis. CMB Cancer 191199 (2019).
Chlebowski, RT et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N.Engl. J.Med. 350991–1004 (2004).
Grodstein, F., Newcomb, PA & Stampfer, MJ Postmenopausal hormone therapy and colorectal cancer risk: a review and meta-analysis. A m. J.Med. 106574–582 (1999).
Camargo, MC et al. Sex hormones, hormonal interventions and gastric cancer risk: a meta-analysis. Cancer epidemiology. Biomark. Prev. 2120–38 (2012).
Brusselaers, N., Maret-Ouda, J., Konings, P., El-Serag, HB & Lagergren, J. Hormonal treatment of menopause and risk of esophageal and stomach cancer. Int. J.Cancer 1401693–1699 (2017).
Wang, Z. et al. Reproductive factors, hormone use and gastric cancer risk: the Singapore Chinese Health Study. Int. J.Cancer 1382837–2845 (2016).
Lopez, V. et al. Menstrual and reproductive factors and risk of gastric and colorectal cancer in Spain. PLoS One 11e0164620 (2016).
Wells, G., Shea, B., and O’Connell, D. Proceedings of the Third Symposium on Systematic Reviews. Beyond the Basics: Improving Quality and Impact. Oxford: The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. (2000).
Higgins, JP & Thompson, SG Quantification of heterogeneity in a meta-analysis. Med Statistics 211539-1558 (2002).
IntHout, J., Ioannidis, JP, Rovers, MM & Goeman, JJ A case for the systematic presentation of prediction intervals in meta-analysis. BMJ open 6e010247 (2016).
Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple graphical test. BMJ 315629–634 (1997).
Duval, S. & Tweedie, R. Trim and fill: A simple funnel chart method to test and adjust for publication bias in meta-analysis. Biometrics 56455–463 (2000).
Patsopoulos, NA, Evangelou, E. & Ioannidis, JP Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical assessment. Int. J. Epidemiol. 371148–1157 (2008).
Kaneko, S., Tamakoshi, A., Ohno, Y., Mizoue, T. & Yoshimura, T. Menstrual and reproductive factors and gastric cancer mortality risk in Japanese postmenopausal women. Control of the causes of cancer 1453–59 (2003).
LaVechia, C. et al. Menstrual and reproductive factors and gastric cancer risk in women. Int. J.Cancer 59761–764 (1994).
Lindblad, M., Rodriguez, LG, Chandanos, E. & Lagergren, J. Hormone replacement therapy and risks of esophageal and gastric adenocarcinomas. Br. J. Cancer 94136–141 (2006).
Duelle, EJ et al. Menstrual and reproductive factors, exogenous hormone use, and gastric cancer risk in a cohort of women from the European Prospective Cancer and Nutrition Survey. A m. J. Epidemiol. 1721384–1393 (2010).
Freedman, North Dakota et al. The association of menstrual and reproductive factors with cancers of the upper gastrointestinal tract in the NIH-AARP cohort. Interdisciplinary cancerology. Int. Jam. Cancer Society 1161572-1581 (2010).
Freedman, North Dakota et al. Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. Intestine 561671-1677 (2007).
Nam, JH et al. The effect of menopausal hormone therapy on gastrointestinal cancer risk and mortality in South Korea: a population-based cohort study. BMC Gastroenterol. 211–2 (2021).
Green, J. et al. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort and meta-analysis. Int. J.Cancer 1302387–2396 (2012).
Frize, S., Kreiger, N., Gallinger, S., Tomlinson, G. & Cotterchio, M. Menstrual and reproductive risk factors and risk of gastric adenocarcinoma in women: results from the Canadian national enhanced cancer surveillance system . Anna. Epidemiol. 16908–916 (2006).
Fernandez, E. et al. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int. J.Cancer 105408–412 (2003).
Grossman, D.C. et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement. JAMA 3182224-2233 (2017).
Rymer, J., Brian, K. & Regan, L. HRT and breast cancer risk. BMJ 36725 (2019).
Hamoda, H. & Moger, S. Looking at HRT in perspective. BMJ 377o1425 (2022).
Fitzmaurice, C. et al. Global, regional and national cancer incidence, mortality, years of life lost, years lived with disability and disability-adjusted life years for 29 cancer groups, 1990 to 2016: A systematic analysis for the study of the burden global morbidity. JAMA Oncol. 41553-1568 (2018).
Xu, CY et al. Prognostic role of estrogen α and β receptors in gastric cancer. Anna. Surg. Oncol. 172503-2509 (2010).
Qin, J. et al. The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells. Mol. Cell. Biochemistry. 39599-107 (2014).
Kim, M.J. et al. Effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell lines. J. Gastr. Cancer 13172–178 (2013).
Rahman, MS & Cao, J. Estrogen receptors in gastric cancer: advances and perspectives. World J. Gastroenterol. 222475–2482 (2016).
Chandanos, E. et al. Exposure to tamoxifen in relation to the development of gastric adenocarcinoma. EUR. J.Cancer 441007-1014 (2008).